418 JOURNAL OF COSMETIC SCIENCE (15) C. D. Toscano and T. R. Guilarte, Lead neurotoxicity: From exposure to molecular effects, Brain Res. Brain Res. Rev., 49(3), 529-554 (2005). (16) S. G. Gilbert and B. Weiss, A rationale for lowering the blood lead action level from 10 to 2 mµg/dL, Neurotoxicology, 27(5), 693-701 (2006). (17) A. Al-Khayat, N. S. Menon, and M. R. Alidina, Acute lead encephalopathy in early infancy-Clinical presentation and outcome, Ann. Trop. Paediatr., 17, 39-44 (1997). (18) H. Narchi, Radiological case of the month, Arch. Pediatr. Adol. Med., 154, 83-84 (2000). (19) F. Fluri, P. Lyrer, A. Gratwohl, A. E. Raetz-Bravo, and A. J. Steck, Lead poisoning from the beauty case: Neurologic manifestations in an elderly woman, Neurology, 69, 929-930 (2007). (20) M.A. Healy, P. G. Harrison, M. Aslam, S.S. Davis, and C. G. Wilson, Lead sulphide and traditional preparations: Routes for ingestion, and solubility and reactions in gastric ffoid,J. Clin. Hosp. Pharm., 7, 169-173 (1982). (21) T. M. Florence, J. L. Stauber, L. S. Dale, D. Henderson, B. E. Izard, and K. Belbin, Skin absorption of ionic lead compounds,]. Austral. Coll. Nutr. Envir. Med., 15(2), 11-12 (1996). (22) C. C. Sun, T. T. Wong, Y. H. Hwang, K. Y. Chao, S. H. Jee, and J. D. Wang, Percutaneous absorp­ tion of inorganic lead compounds, Am. Ind. Hyg. Assoc.]., 63(5), 641-646 (2002). (23) C. Gardella, Lead exposure in pregnancy: A review of the literature and argument for routine prenatal screening, Obstet. Gynaec. Survey, 56(4), 231-238 (2001). (24) J. Y. Taylor and T. G. Holtrop, Yemeni families and child lead screening in Detroit,]. Transcult. Nurs., 18(1), 63-69 (2007). (25) World Health Organization, Regional Office for the Eastern Mediterranean, Regional Centre for Environmental Health Activities (Amman, Jordan), A Review of Literature on Healthy Environments for Children in the Eastern Mediterranean Region: Status of Childhood Lead Exposure, World Health Organi­ zation (2005). (26) M. P. Dieter, Toxicity and carcinogenicity studies of boric acid in male and female B6C3F mice, Environ. Health Perspect., 102(Suppl. 7), 93-97 (1994). (27) P. Harrigan, Volcanic Arabia, Saudi Aramco World, 57(2), 2-13 (2006). (28) Republic of Yemen, Ministry of Oil and Minerals, Geological Survey and Minerals Resources Board, Investment Opportunities of the Metallic Minerals in Yemen, Ministry of Oil and Minerals (2006). (29) M. Aslam, S.S. Davis, and M.A.Healy, Heavy metals in some Asian medicines and cosmetics, Public Health, 93, 27 4-284 (1979). (30) N. P. Fernando, M.A. Healy, M. Aslam, S.S. Davis, and A. Hussein, Lead poisoning and traditional practices: The consequences for world health. A study in Kuwait, Public Health, 95, 250-260 (1981). (31) M.A.Healy, M. Aslam, and 0. A. Bamgboye, Traditional medicine and lead-containing preparations in Nigeria, Public Health, 98, 26-32 (1984). (32) S. A. F. Al-Hazzaa and P. M. Krahn, Kohl: A hazardous eyeliner, Int. Ophthalmol., 19, 83-88 (1995). (33) A. D. Hardy, R. I. Walton, R. Vaishnav. K. A. Myers, M. R. Power, and D. Pirrie, "Egyptian Eye Cosmetics ("Kohls"): Past and Present," in Physical Techniques in the Study of Art, Archaeology and Cultural Heritage, D. Bradley and C. Creagh, Eds. (Elsevier, Amsterdam, 2006), Chapter 5. (34) C. Parry and J. Eaton, Kohl: A lead-hazardous eye makeup from the Third World to the First World, Environ. Health PenjJeC"t., 94, 121-123 (1991). (35) I. M. Madany and M. S. Akhter, Lead levels in some eye cosmetics used in Bahrain,]. Environ. Sci. Health {A}, 27(6), 1541-1547 (1992). (36) A. Al-Kaff, A. Al-Rajhi, K. Tabbora, and A. El-Yazigi, Kohl-The traditional eyeliner: Use and analysis, Ann. Saudi Med., 13(1), 26-30 (1993). (3 7) A. M. Syed, M. Qadiruddin, K. Shirin, and Z. B. Hashmi, Determination of inorganic components including minor and trace elements in surma (kohl) formulations, Pak. ]. Sci. Ind. Res., 37(10), 411-413 (1994). (38) I. A. Al-Saleh and L. Coate, Lead exposure in Saudi Arabia from the use of traditional cosmetics and medical remedies, Environ. Geochem. Health, 17, 29-31 (1995). (39) R. Chappell, P. Billig, E. Brantly, S. Ault, and H. S. Ezzeldin, Lead Exposure Abatement Plan for Egypt: Results of Environmental Sampling for Lead, Environmental Health Project, Activity Report No. 32 (prepared for the USAID Mission to Egypt under EHP Activity No. 256-CC) (1997). (40) N. Lekouch, A. Sedki, N. Nejmeddine, and S. Gamon, Lead and traditional Moroccan pharmacopoeia, Sci. Total Environ., 280, 39-43 (2001). (41) R. M. Al-Ashban, M. Aslam, and A.H.Shah, Kohl (surma): A toxic traditional eye cosmetic study in Saudi Arabia, Pub. Health, 118(4), 292-298 (2004).

J. Cosmet. Sci., 59, 419-430 (September/October 2008) Anti-inflammatory activity of Crinum asiaticum Linne var. japonicum extract and its application as a cosmeceutical ingredient YOUNG HEUI KIM, KI HO KIM, CHANG SUNG HAN, SUN HEE PARK, HONG CHUL YANG, BANG YONG LEE, SANG-YONG EOM, YOUNG-SIL KIM, JONG-HEON KIM, and NAM HO LEE, R&D Center, Bioland Ltd., Songjeong, Byongchon, Cheonan-si, Chungnam, 330-863 (Y.H.K., K.H.K., C.S.H., S.H.P., H.C. Y., B. Y.L.), R&D Center, Charmzone, 1720-4 Taejang 2-dong, Wonju-si, Kangwon-do, 220-962 (S.-Y.E., Y.-S.K., ].-H.K.), and Department of Chemistry, College of Natural Science, Cheju National University, Ara I-dong, Jeju, 690-7 56 (N.H.L.), Republic of Korea Accepted for publication April 9, 2008. Presented at the 2007 ASCS Conference, Singapore, March 7-9, 2007. Synopsis Crinurn asiaticurn Linne var. japonicurn has long been used as a rheumatic remedy, as an anti-pyretic and as an anti-ulcer treatment, and for the alleviation of local pain and fever in Korea and Malaysia. In order to investigate the possibility of Crinurn asiaticurn Linne var. japonicurn extract as a cosmetic ingredient, we measured its anti-inflammatory effect by its inhibition of iNOS (inducible nitric oxide synthase) and the release of PGE2, IL-6, and IL-8. We also measured its anti-allergic effect by its inhibition of 13-hexosamidase release. An HPLC experiment after extraction with 95% EtOH at pH 3.5 showed that Crinurn asiaticurn Linne var. japonicurn was mainly composed of lycorine (up to 1 %), a well-known immunosuppressor. The content of lycorine varied, depending on the type of plant tissue analyzed and the extraction method. In an anti-inflammatory assay for inhibition of nitric oxide formation on lipopolysaccharide (LPS)-activated mouse macrophage RAW 264. 7 cells, the ethanol extract of Crinurn asiaticurn showed an inhibitory activity of NO production in a dose-dependent manner (IC50 = 58.5 µg/ml). Additional study by RT-PCR demonstrated that the extract of Crinurn asiaticurn significantly suppressed the expression of the iNOS gene. Moreover, the extract of Crinurn asiaticurn did not show any cytotoxicity, but did show a cell proliferation effect against LPS (a 10�60% increase in cell viability). In an assay to determine inhibition of the H 2 02-activated release of PGE2, IL-6, and IL-8 in human normal fibroblast cell lines, the release of PGE2 and IL-6 was almost completely inhibited above concentrations of 0.05 % and 1 %, respectively. Moreover, the release of IL-8 was completely inhibited over the entire range of concentration (0.0025%). In order to investigate the Address all correspondence to Young Heui Kim. 419